NEW YORK, NY--(Marketwired - Apr 7, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. (NASDAQ: TPIV), an NNW client focused on leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms.
The publication is entitled, "Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies." It discusses the need for advanced cancer treatment options and how a handful of biopharma companies are rising to meet this demand.
To view the full publication, visit: https://www.networknewswire.com/global-oncology-market-gains-ground-driven-innovative-cancer-treatment-therapies/
"Clinical-stage immune-oncology company TapImmune, Inc. (NASDAQ: TPIV) is particularly focused on the potential of immunotherapy -- which stimulates the body's immune response to prevent or treat diseases -- for the treatment of women's cancers with high recurrence rates, namely ovarian and breast cancer. Because TapImmune's innovations center on immunotherapy, it is worth noting that ovarian and breast cancer are typically resistant to most immunotherapies. The company's approach to immune-oncology therapy, however, demonstrates unique potential to go against the grain...The goal is to trigger a natural immune response against both the primary tumor as well as metastatic disease to help prevent cancer recurrence and as a second-line therapy for women who are resistant to first-line therapies. To achieve this goal, the vaccines are comprised of naturally processed antigens from human immune responses recognized by more than 85% of the population, as well as a mix of class I and class II antigens to achieve an anti-tumor immune response across a broader patient population."
About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.
For more information, visit www.tapimmune.com
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and contributing writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://nnw.fm/Disclaimer
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.